Optimizing radioimmunoconjugate delivery in the treatment of solid tumor

Cancer Treatment Reviews

Volumn 38, Issue 7, 2012, Pages 854-860

  Huang, Chen Yu ^a   Pourgholami, Mohammad H ^a,b   Allen, Barry J ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST GEORGE HOSPITAL   (Australia)

Author keywords

Alpha radiation; Diffusion; Radioimmunoconjugate; Radioimmunotherpy; Tumor vasculature; Vascular permeability

Indexed keywords

ACTINIUM 225; ALBENDAZOLE; ANTIBODY CONJUGATE; ASTATINE 211; BEVACIZUMAB; BISMUTH 213; COMBRETASTATIN A4 PHOSPHATE; DEXTRAN DERIVATIVE; IBRITUMOMAB TIUXETAN; LYSINE; PENTETREOTIDE IN 111; TETRAXETAN; TOSITUMOMAB I 131; VASCULOTROPIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ALPHA RADIATION; AUGER ELECTRON SPECTROSCOPY; BLOOD VESSEL PERMEABILITY; BRAIN TUMOR; CANCER CELL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER THERAPY; CELL MIGRATION; CELL SURVIVAL; DIGESTIVE SYSTEM CANCER; DOSIMETRY; DOUBLE STRANDED DNA BREAK; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG EXTRAVASATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG PENETRATION; GLIOMA; GLOMERULUS BASEMENT MEMBRANE; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HEMATOLOGIC MALIGNANCY; HUMAN; LIVER TOXICITY; LUNG METASTASIS; METASTATIC MELANOMA; MICROMETASTASIS; MICROVASCULAR ENDOTHELIAL CELL; NEUROENDOCRINE TUMOR; NEUROLOGIC DISEASE; NONHODGKIN LYMPHOMA; NONHUMAN; PANCREAS TUMOR; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLASMA HALF LIFE; PROCESS OPTIMIZATION; RADIOIMMUNOTHERAPY; RECURRENT CANCER; REVIEW; SOLID TUMOR; TARGET CELL; TISSUE PRESSURE; TUMOR BLOOD FLOW; TUMOR VASCULARIZATION;

ANIMALS; HUMANS; IMMUNOCONJUGATES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RADIOIMMUNOTHERAPY;

EID: 84865410155     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2011.12.005     Document Type: Review

References (84)

1. Rajkumar V., Dearling J.L., Packard A., Pedley R.B. Radioimmunotherapy: optimizing delivery to solid tumors. Ther Deliv 2011, 2:567-572.
2. Wu A.M., Senter P.D. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 2005, 23:1137-1146.
3. Jang S.H., Wientjes M.G., Lu D., Au J.L.S. Drug delivery and transport to solid tumors. Pharm Res 2003, 20:1337-1350.
4. Verhaar-Langereis M.J., Zonnenberg B.A., de Klerk J.M.H., Blijham G.H. Radioimmunodiagnosis and therapy. Cancer Treat Rev 2000, 26:3-10.
5. Williams L.E., DeNardo G.L., Meredith R.F. Targeted radionuclide therapy. Med Phys 2008, 35:3062-3068.
6. Belloni D., Scabini S., Foglieni C., Veschini L., Giazzon A., Colombo B., et al. The vasostatin-I fragment of chromogranin A inhibits VEGF-induced endothelial cell proliferation and migration. FASEB J 2007, 21:3052-3062.
7. Vaupel P., Harrison L. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. The Oncologist 2004, 9:4-9.
8. Fukumura D., Jain R.K. Imaging angiogenesis and the microenvironment. APMIS 2008, 116:695-715.
9. Hirschi K.K., Skalak T.C., Peirce S.M., Little C.D. Vascular assembly in natural and engineered tissues. Ann N Y Acad Sci 2002, 961:223-242.
10. Jain R.K. Molecular regulation of vessel maturation. Nat Med 2003, 9:685-693.
11. Less J.R., Posner M.C., Skalak T.C., Wolmark N., Jain R.K. Geometric resistance and microvascular network architecture of human colorectal carcinoma. Microcirculation 1997, 4:25-33.
12. Vaupel P., Kallinowski F., Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 1989, 49:6449-6465.
13. Hashizume H., Baluk P., Morikawa S., McLean J.W., Thurston G., Roberge S., et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000, 156:1363-1380.
14. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
15. Abramsson A., Lindblom P., Betsholtz C. Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J Clin Invest 2003, 112:1142-1151.
16. Kötz B., West C., Saleem A., Jones T., Price P. Blood flow and Vd (water): both biomarkers required for interpreting the effects of vascular targeting agents on tumor and normal tissue. Mol Cancer Ther 2009, 8:303-309.
17. Tozer G.M., Kanthou C., Baguley B.C. Disrupting tumour blood vessels. Nat Rev Cancer 2005, 5:423-435.
18. Fukumura D., Xu L., Chen Y., Gohongi T., Seed B., Jain R.K. Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res 2001, 61:6020-6024.
19. Loevinger R., Budinger T.F., Watson E.E. MIRD primer for absorbed dose calculations 1988, Society of Nuclear Medicine, New York.
20. Howell R.W., Wessels B.W., Loevinger R., Watson E.E., Bolch W.E., Brill A.B., et al. The MIRD perspective 1999. Medical Internal Radiation Dose Committee. J Nucl Med 1999, 40:3S-10S.
21. Gimbrone M.A., Leapman S.B., Cotran R.S., Folkman J. Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 1972, 136:261-276.
22. Baxter L.T., Jain R.K. Transport of fluid and macromolecules in tumors I. Role of interstitial pressure and convection. Microvasc Res 1989, 37:77-104.
23. Sevick E.M., Jain R.K. Viscous resistance to blood flow in solid tumors: effect of hematocrit on intratumor blood viscosity. Cancer Res 1989, 49:3513-3519.
24. Sevick E.M., Jain R.K. Geometric resistance to blood flow in solid tumors perfused ex vivo: effects of tumor size and perfusion pressure. Cancer Res 1989, 49:3506-3512.
25. Yuan F., Dellian M., Fukumura D., Leunig M., Berk D.A., Torchilin V.P., et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995, 55:3752-3756.
26. Nagy J., Benjamin L., Zeng H., Dvorak A., Dvorak H. Vascular permeability, vascular hyperpermeability and angiogenesis. Angiogenesis 2008, 11:109-119.
27. Jain R.K. Transport of molecules in the tumor interstitium: a review. Cancer Res 1987, 47:3039-3051.
28. Deen W.M. Hindered transport of large molecules in liquid-filled pores. AIChE J 1987, 33:1409-1425.
29. Brown E.B., Boucher Y., Nasser S., Jain R.K. Measurement of macromolecular diffusion coefficients in human tumors. Microvasc Res 2004, 67:231-236.
30. Hamoudeh M., Kamleh M.A., Diab R., Fessi H. Radionuclides delivery systems for nuclear imaging and radiotherapy of cancer. Adv Drug Deliv Rev 2008, 60:1329-1346.
31. Nugent L.J., Jain R.K. Extravascular diffusion in normal and neoplastic tissues. Cancer Res 1984, 44:238-244.
32. Pluen A., Boucher Y., Ramanujan S., McKee T.D., Gohongi T., di Tomaso E., et al. Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors. Proc Natl Acad Sci USA 2001, 98:4628-4633.
33. Ansiaux R., Baudelet C., Jordan B.F., Beghein N., Sonveaux P., De Wever J., et al. Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. Clin Cancer Res 2005, 11:743-750.
34. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
35. Escorcia F.E., Henke E., McDevitt M.R., Villa C.H., Smith-Jones P., Blasberg R.G., et al. Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors. Cancer Res 2010, 70:9277-9286.
36. Fukumura D., Jain R.K. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res 2007, 74:72-84.
37. Miller D.W., Vosseler S., Mirancea N., Hicklin D.J., Bohlen P., Volcker H.E., et al. Rapid vessel regression, protease inhibition, and stromal normalization upon short-term vascular endothelial growth factor receptor 2 inhibition in skin carcinoma heterotransplants. Am J Pathol 2005, 167:1389-1403.
38. Vosseler S., Mirancea N., Bohlen P., Mueller M.M., Fusenig N.E. Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants. Cancer Res 2005, 65:1294-1305.
39. Winkler F., Kozin S.V., Tong R.T., Chae S.-S., Booth M.F., Garkavtsev I., et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004, 6:553-563.
40. Tong R.T., Boucher Y., Kozin S.V., Winkler F., Hicklin D.J., Jain R.K. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004, 64:3731-3736.
41. Singh Jaggi J., Henke E., Seshan S.V., Kappel B.J., Chattopadhyay D., May C., et al. PLoS ONE 2007, 2:e267.
42. Mazeron R., Anderson B., Supiot S., Paris F., Deutsch E. Current state of knowledge regarding the use of antiangiogenic agents with radiation therapy. Cancer Treat Rev 2011, 37:476-486.
43. Verhoeff J.J.C., Stalpers L.J.A., Van Noorden C.J.F., Troost D., Ramkema M.D., van Bree C., et al. Angiogenesis inhibitor DC101 delays growth of intracerebral glioblastoma but induces morbidity when combined with irradiation. Cancer Letters 2009, 285:39-45.
44. Narayana A., Kelly P., Golfinos J., Parker E., Johnson G., Knopp E., et al. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg 2009, 110:173-180.
45. Narang A.S., Varia S. Role of tumor vascular architecture in drug delivery. Adv Drug Deliv Rev 2011, 63:640-658.
46. Dvorak H.F., Sioussat T.M., Brown L.F., Berse B., Nagy J.A., Sotrel A., et al. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. J Exp Med 1991, 174:1275-1278.
47. Tang N., Du G.J., Wang N., Liu C.C., Hang H.Y., Liang W. Improving penetration in tumors with nanoassemblies of phospholipids and doxorubicin. J Natl Cancer Inst 2007, 99:1004-1015.
48. Pourgholami M.H., Khachigian L.M., Fahmy R.G., Badar S., Wang L., Chu S.W., et al. Albendazole inhibits endothelial cell migration, tube formation, vasopermeability, VEGF receptor-2 expression and suppresses retinal neovascularization in ROP model of angiogenesis. Biochem Biophys Res Commun 2010, 397:729-734.
49. Pourgholami M.H., Morris D.L. Inhibitors of vascular endothelial growth factor in cancer. Cardiovasc Hematol Agents Med Chem 2008, 6:343-347.
50. Pourgholami M.H., Yan Cai Z., Lu Y., Wang L., Morris D.L. Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice. Clin Cancer Res 2006, 12:1928-1935.
51. Steiger U., Cotting J., Reichen J. Albendazole treatment of echinococcosis in humans: effects on microsomal metabolism and drug tolerance. Clin Pharm Ther 1990, 47:347-353.
52. Taghian A.G., Abi-Raad R., Assaad S.I., Casty A., Ancukiewicz M., Yeh E., et al. Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications. J Clin Oncol 2005, 23:1951-1961.
53. Jain R.K. Transport of molecules across tumor vasculature. Cancer Metastasis Rev 1987, 6:559-593.
54. Hinnen P., Eskens F.A.L.M. Vascular disrupting agents in clinical development. Br J Cancer 2007, 96:1159-1165.
55. Meyer T., Gaya A.M., Dancey G., Stratford M.R.L., Othman S., Sharma S.K., et al. A phase i trial of radioimmunotherapy with 131i-a5b7 anti-cea antibody in combination with combretastatin-a4-phosphate in advanced gastrointestinal carcinomas. Clin Cancer Res 2009, 15:4484-4492.
56. Pedley R.B., Hill S.A., Boxer G.M., Flynn A.A., Boden R., Watson R., et al. Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-o-phosphate. Cancer Res 2001, 61:4716-4722.
57. Kremmidiotis G., Leske A.F., Lavranos T.C., Beaumont D., Gasic J., Hall A., et al. BNC105: a novel tubulin polymerization inhibitor that selectively disrupts tumor vasculature and displays single-agent antitumor efficacy. Mol Cancer Ther 2010, 9:1562-1573.
58. Jain R.K. Delivery of molecular and cellular medicine to solid tumors. J Controlled Release 1998, 53:49-67.
59. Dietmar W.S. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents. Cancer Treat Rev 2011, 37:63-74.
60. Rocha S., Adams R. Molecular differentiation and specialization of vascular beds. Angiogenesis 2009, 12:139-147.
61. McDevitt M.R., Ma D., Simon J., Frank R.K., Scheinberg D.A. Design and synthesis of 225Ac radioimmunopharmaceuticals. Appl Radiat Isot 2002, 57:841-847.
62. Raja C., Graham P., Abbas Rizvi S.M., Song E., Goldsmith H., Thompson J., et al. Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma. Cancer Biol Ther 2007, 6:846-852.
63. Allen B.J. Clinical trials of targeted alpha therapy for cancer. Rev Recent Clin Trials 2008, 3:185-191.
64. Dietmar W.S. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents. Cancer Treatment Reviews 2011, 37:63-74.
65. Allen B.J., Raja C., Rizvi S., Song E.Y., Graham P. Tumour anti-vascular alpha therapy: a mechanism for the regression of solid tumours in metastatic cancer. Phys Med Biol 2007, 52:9-15.
66. Holliger P., Hudson P.J. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005, 23:1126-1136.
67. Dreher M.R., Liu W.G., Michelich C.R., Dewhirst M.W., Yuan F., Chilkoti A. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst 2006, 98:335-344.
68. Behr T.M., Goldenberg D.M., Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med Mol Imaging 1998, 25:201-212.
69. Li L., Olafsen T., Anderson A.-L., Wu A., Raubitschek A.A., Shively J.E. Reduction of kidney uptake in radiometal labeled peptide linkers conjugated to recombinant antibody fragments. Site-specific conjugation of DOTA-peptides to a cys-diabody. Bioconjug Chem 2002, 13:985-995.
70. Zalutsky M.R., Reardon D.A., Akabani G., Coleman R.E., Friedman A.H., Friedman H.S., et al. Clinical experience with α-particle-emitting 211at: treatment of recurrent brain tumor patients with 211at-labeled chimeric antitenascin monoclonal antibody 81c6. J Nucl Med 2008, 49:30-38.
71. Rosenblat T.L., McDevitt M.R., Mulford D.A., Pandit-Taskar N., Divgi C.R., Panageas K.S., et al. Sequential cytarabine and α-particle immunotherapy with bismuth-213-lintuzumab (hum195) for Acute Myeloid Leukemia. Clin Cancer Res 2010, 16:5303-5311.
72. Nilsson S., Larsen R.H., Fosså S.D., Balteskard L., Borch K.W., Westlin J.-E., et al. First clinical experience with α-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 2005, 11:4451-4459.
73. A Double-blind, randomised, multiple dose, phase iii, multicentre study of alpharadin in the treatment of patients with symptomatic hormone refractory prostate cancer with skeletal metastases. Available from: http://clinicaltrials.gov/ct2/show/NCT00699751.
74. Song H., Hobbs R.F., Vajravelu R., Huso D.L., Esaias C., Apostolidis C., et al. Radioimmunotherapy of breast cancer metastases with α-particle emitter 225ac: comparing efficacy with 213Bi and 90Y. Cancer Res 2009, 69:8941-8948.
75. Wiseman G.A., Witzig T.E. Yttrium-90 (90Y) Ibritumomab Tiuxetan (Zevalin®) induces long-term durable responses in patients with relapsed or refractory b-cell non-Hodgkin's lymphoma. Cancer Biother Radiopharm 2005, 20:185-188.
76. Wahl R.L. Tositumomab and 131I therapy in non-Hodgkin's Lymphoma. J Nucl Med 2005, 46:40-128.
77. Kwekkeboom D.J., Teunissen J.J., Bakker W.H., Kooij P.P., de Herder W.W., Feelders R.A., et al. Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. Journal of Clinical Oncology 2005, 23:2754-2762.
78. Valkema R., de Jong M., Bakker W.H., Breeman W.A.P., Kooij P.P.M., Lugtenburg P.J., et al. Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: the rotterdam experience. Semin Nucl Med 2002, 32:110-122.
79. Sgouros G. Alpha-particles for targeted therapy. Adv Drug Deliv Rev 2008, 60:1402-1406.
80. McDevitt M.R., Sgouros G., Finn R.D., Humm J.L., Jurcic J.G., Larson S.M., et al. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med Mol Imaging 1998, 25:1341-1351.
81. McDevitt M.R., Ma D., Lai L.T., Simon J., Borchardt P., Frank R.K., et al. Tumor therapy with targeted atomic nanogenerators. Science 2001, 294:1537-1540.
82. Sgouros G., Roeske J.C., McDevitt M.R., Palm S., Allen B.J., Fisher D.R., et al. MIRD pamphlet no. 22 (abridged): radiobiology and dosimetry of {alpha}-particle emitters for targeted radionuclide therapy. J Nucl Med 2010, 51:311-328.
83. Allen B.J., Rizvi S., Li Y., Tian Z., Ranson M. In vitro and preclinical targeted alpha therapy for melanoma, breast, prostate and colorectal cancers. Crit Rev Oncol Hematol 2001, 39:139-146.
84. Roeske J.C., Aydogan B., Bardies M., Humm J.L. Small-scale dosimetry: challenges and future directions. Semin Nucl Med 2008, 38:367-383.